SEATTLE — In this video, Eleonora M. Lad, MD, PhD, discusses presentations from the ARVO annual meeting on real-world use of faricimab and the use of pegcetacoplan in the treatment of geographic atrophy.
A notable presentation on the last day of the meeting evaluated the use of pegcetacoplan vs. avacincaptad pegol in geographic atrophy, according to Lad, vice chair of ophthalmology clinical research at Duke Health.
The analysis suggested a greater reduction in geographic atrophy lesion growth with monthly pegcetacoplan vs. monthly avacincaptad pegol.
Lad said this research is important